Agenus (AGEN) to Release Quarterly Earnings on Thursday

Agenus (NASDAQ:AGEN) is scheduled to be releasing its earnings data before the market opens on Thursday, August 8th. Analysts expect Agenus to post earnings of ($1.33) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Agenus (NASDAQ:AGEN) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.58) by $0.54. The company had revenue of $28.01 million during the quarter, compared to analysts’ expectations of $40.70 million. On average, analysts expect Agenus to post $-11 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Agenus Stock Up 3.6 %

NASDAQ AGEN opened at $5.43 on Wednesday. The company has a 50-day simple moving average of $12.94 and a two-hundred day simple moving average of $12.19. Agenus has a 12-month low of $4.78 and a 12-month high of $32.00. The firm has a market cap of $114.02 million, a price-to-earnings ratio of -0.42 and a beta of 1.33.

Analyst Ratings Changes

Several analysts have issued reports on the stock. William Blair lowered shares of Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. StockNews.com started coverage on shares of Agenus in a research note on Wednesday, April 17th. They set a “hold” rating for the company. Robert W. Baird downgraded shares of Agenus from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $8.00 in a research note on Friday, July 19th. HC Wainwright downgraded shares of Agenus from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $40.00 to $9.00 in a research note on Thursday, July 18th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $7.00 price objective (up from $3.00) on shares of Agenus in a research note on Friday, July 19th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $31.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.